

an Open Access Journal by MDPI

## Astaxanthin: A Potential Therapeutic Agent

Guest Editor:

### Dr. Graciela Pavon-Djavid

Laboratory for Vascular  
Translational Science,  
Cardiovascular Bioengineering,  
Université Sorbonne Paris Nord-  
INSERM U1148, 99 Av. Jean-  
Baptiste Clément, 93430  
Villetaneuse, France

Deadline for manuscript  
submissions:

**closed (15 June 2020)**

### Message from the Guest Editor

Founding new therapeutic molecules capable of maintaining cellular redox homeostasis and blocking oxidative stress are challenges of crucial importance.


Because of its anti-inflammatory and antioxidant properties, astaxanthin, a xanthophyll carotenoid extracted from marine organisms and microalgae, has been proposed for repairing and protecting cells and tissues or as a nutraceutical/cosmeceutical ingredient to prevent oxidative stress-related diseases. Epidemiological studies suggest that astaxanthin prevents the free radical-dependent oxidation of LDL, cholesterol, proteins, or DNA, by capturing free radicals and by reducing stress induced by ROS.

This Special Issue aims to highlight recent research about astaxanthin's potential as a therapeutic agent. Despite significant growing evidence suggesting that astaxanthin has a potential health-promoting effect in the prevention and treatment of several pathologies, research advances need to be reported. Original research (in vitro, in vivo, and clinical) and reviews to highlight the therapeutic potential effect of astaxanthin are encouraged to be presented in this Special Issue.



[mdpi.com/si/23056](https://mdpi.com/si/23056)

# Special Issue



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Bill J. Baker

Department of Chemistry,  
University of South Florida, 4202  
E. Fowler Ave., CHE 205, Tampa,  
FL 33620-5250, USA

## Message from the Editor-in-Chief

During the past few decades there has been an ever increasing number of novel compounds discovered in the marine environment. This is exemplified by the robust preclinical and clinical pipeline that currently exists for marine natural products. *Marine Drugs* is inviting contributions on new advances in marine biotechnology, pharmacology, chemical ecology, synthetic biology, and genomics approaches related to the discovery of therapeutically relevant marine natural products. Our goal is to share your contribution in a timely fashion and in a manner that will be valued by the scientific community.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [MEDLINE](#), [PMC](#), [Embase](#), [PubAg](#), [MarinLit](#), [AGRIS](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmacology, Toxicology and Pharmaceutics (miscellaneous))

## Contact Us

---

*Marine Drugs* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/marinedrugs](http://mdpi.com/journal/marinedrugs)  
[marinedrugs@mdpi.com](mailto:marinedrugs@mdpi.com)  
[X@Marine\\_Drugs](#)